Subject:
- Active Substance: Sorafenib
- Name: Nexavar®
- Therapeutic area: Thyroid carcinoma
- Pharmaceutical company: Bayer Pharma AG
Time table:
- Publication of final assessment: 17.03.2015
Assessment information:
- Title: Sorafenib for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma refractory to radioactive iodine
- Author/Co-Author: AIFA (Italy), INFARMED (Portugal)
- Dedicated Reviewers: RIZIV-INAMI (Belgium), FIMEA (Finland), GYEMSZI (Hungary), NCPE (Ireland), MoH Slovak Republic (Slovakia)
G-BA assessment not available
Reason: First launch of Sorafenib was in 2010 (pre-AMNOG).